Session I: Opening Session

Discussant: LBA 0-9, LBA 0-10

Wednesday, June 29, 2022

13:25 – 13:30

Location: Auditorium A; Level 0

Discussant(s)

LBA O-9: Botensilimab, a novel innate/adaptive immune activator, plus balstilimab (anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer - Anthony B. El-Khoueiry, et al
LBA 0-10